News

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
Good morning. Biotech was not faring well yesterday, after we got the news that Vinay Prasad was chosen to be the next ...
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and ...
In the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics ...
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...
The firm notes Tuesday has been “a doozy of a day” for Sarepta, with the announcement of Vinay Prasad as the new head of the FDA’s CBER and a miss on Q1 earnings, where Elevidys net revenue came in ...
“Potential exposure to these substances is still quite small, thank goodness,” Jim Crotty, who served for over a decade in ...